BioCentury | Aug 17, 2009
Company News

Antisoma, Bryan Oncor deal

...Antisoma granted cancer company Bryan Oncor an exclusive, worldwide license to develop and commercialize P2045. The somatostatin...
...rhenium-188 isotope has completed a Phase I trial to treat non-small cell lung cancer (NSCLC). Bryan Oncor...
...acquisition of Xanthus Pharmaceuticals Inc. (see BioCentury, June 16, 2008). Antisoma plc (LSE:ASM), London, U.K. Bryan Oncor Inc....
Items per page:
1 - 1 of 1
BioCentury | Aug 17, 2009
Company News

Antisoma, Bryan Oncor deal

...Antisoma granted cancer company Bryan Oncor an exclusive, worldwide license to develop and commercialize P2045. The somatostatin...
...rhenium-188 isotope has completed a Phase I trial to treat non-small cell lung cancer (NSCLC). Bryan Oncor...
...acquisition of Xanthus Pharmaceuticals Inc. (see BioCentury, June 16, 2008). Antisoma plc (LSE:ASM), London, U.K. Bryan Oncor Inc....
Items per page:
1 - 1 of 1